12885_2019_5704_MOESM3_ESM.tif (1.24 MB)
Additional file 3: of Pazopanib has equivalent anti-tumor effectiveness and lower Total costs than Sunitinib for treating metastatic or advanced renal cell carcinoma: a meta-analysis
figure
posted on 2019-05-23, 05:00 authored by Huan Deng, Yu Huang, Zhengdong Hong, Xuhui Yuan, Zhi Cao, Yiping Wei, Wenxiong ZhangFigure S2. Sensitivity analysis of ORR (A) and DCR (B) (TIF 1268 kb)